Semaglutide Dose Calculator

The Semaglutide Dose Escalation Calculator models the FDA-approved dose titration schedule for semaglutide, which is available as Wegovy (for chronic weight management at doses up to 2.4 mg weekly) and Ozempic (for type 2 diabetes at doses up to 2.0 mg weekly). Semaglutide requires a gradual dose escalation over 16 to 20 weeks to minimize gastrointestinal side effects, and this calculator tracks the patient's current position in the titration schedule, identifies the correct pen device for each dose level, and projects when the target maintenance dose will be reached. The dose escalation protocol exists because semaglutide causes significant gastrointestinal side effects, particularly nausea, vomiting, and diarrhea, when initiated at full therapeutic doses. By starting at 0.25 mg weekly and increasing every 4 weeks, the body gradually adapts to the GLP-1 receptor stimulation, reducing the incidence and severity of side effects. In the STEP 1 trial, approximately 44 percent of patients on semaglutide 2.4 mg reported nausea at some point during treatment, but the slow titration schedule helped most patients manage through these early side effects without discontinuing. The Wegovy dose escalation follows five steps: 0.25 mg for weeks 1 to 4, 0.5 mg for weeks 5 to 8, 1.0 mg for weeks 9 to 12, 1.7 mg for weeks 13 to 16, and 2.4 mg from week 17 onward as the maintenance dose. Each dose level requires a different pen device with a distinct color label. Ozempic follows a similar but compressed schedule: 0.25 mg for weeks 1 to 4, 0.5 mg from week 5 onward (initial maintenance), with optional increases to 1.0 mg and then 2.0 mg based on glycemic response. Understanding which pen to use and when to advance is essential for safe and effective therapy. This calculator is used by patients who need to track their position in the titration schedule, by physicians and nurse practitioners who are prescribing semaglutide for the first time and want to confirm the correct dose advancement timeline, by pharmacists who need to verify that the correct pen device is being dispensed for the patient's current titration phase, and by prior authorization teams who need to confirm that the dose matches the approved escalation schedule before authorizing refills.

DigiCalcs delivers precision-engineered tools for engineers and STEM professionals.

1. 1Select the semaglutide brand and indication. Wegovy is prescribed for chronic weight management and follows a 5-step titration to 2.4 mg. Ozempic is prescribed for type 2 diabetes and follows a 3 to 4-step titration to 1.0 mg or 2.0 mg. The dose schedules differ between these brands, and the calculator adjusts the titration timeline and pen device assignments accordingly. Patients switching between brands (for example, from Ozempic to Wegovy due to insurance changes) can enter their current dose to determine where they fall in the new brand's titration schedule.
2. 2Enter the date you started semaglutide therapy or your current week number. The calculator uses this to determine your exact position in the titration schedule. If you are restarting after a gap in treatment, the calculator applies the FDA-recommended guidance: if you missed 2 or fewer consecutive weekly doses, resume at the same dose; if you missed more than 2 weeks, consider restarting at a lower dose to re-acclimate and reduce the risk of gastrointestinal side effects upon resumption.
3. 3The calculator displays your current prescribed dose, the corresponding pen device (identified by dose strength and label color), and the injection volume. Wegovy pens are pre-filled single-dose devices, while Ozempic pens are multi-dose devices that deliver multiple injections per pen. Understanding the pen mechanics is important because Ozempic pens are dialed to different dose markings depending on the titration phase, while Wegovy pens are fixed-dose and require a new pen type at each escalation step.
4. 4Review the complete titration timeline showing all dose escalation steps, the date of each planned dose increase, and the expected time to reach your target maintenance dose. The calculator accounts for the 4-week intervals between dose increases and highlights any upcoming transitions. For patients experiencing significant side effects at their current dose, the calculator can model extended titration (staying at a dose for 8 weeks instead of 4) and show how this affects the timeline to maintenance.
5. 5The calculator provides pen supply management information showing how many pens you need at each dose level, when to request refills, and typical insurance authorization timelines for dose transitions. Since each Wegovy dose level requires a different pen device with a unique NDC (National Drug Code), your pharmacy needs to order the correct pen for each transition. Planning ahead by 1 to 2 weeks prevents gaps in treatment due to pharmacy stocking delays or prior authorization requirements for the new dose level.
6. 6For patients experiencing dose-limiting side effects, the calculator includes a tolerability management module. Common strategies include extending the duration at the current dose (spending 8 weeks instead of 4 at a dose level before escalating), taking the injection in the evening instead of the morning to sleep through peak nausea, eating smaller meals on injection day, and using anti-nausea medications like ondansetron during the first 2 to 3 days after each injection. The calculator adjusts the projected timeline based on any dose delays entered.
7. 7The output includes a printable dose escalation card that patients can share with their pharmacy and healthcare provider, ensuring everyone involved in their care is aligned on the current and upcoming dose schedule. This is particularly valuable for patients managing their titration across multiple providers or during transitions between healthcare systems.

• !Skipping dose levels or escalating faster than the 4-week intervals in an attempt to reach the maintenance dose sooner is dangerous because it dramatically increases the risk of severe gastrointestinal side effects including persistent nausea, vomiting, and in rare cases pancreatitis, and it does not meaningfully accelerate weight loss because most of the benefit comes from sustained treatment at the maintenance dose rather than rapid dose escalation.
• !Using the wrong pen device for the current dose level is a medication error that can result in either underdosing (if using a lower-dose pen at a higher titration step) or overdosing (if using a higher-dose pen prematurely), because Wegovy pens are fixed-dose devices that cannot be adjusted, and patients must receive the specific pen that matches their current titration phase.
• !Restarting at the previous dose after a treatment gap of more than 2 to 3 weeks without stepping down is a common cause of severe side effects upon resumption, because the body's tolerance to GLP-1 receptor agonism decreases during the gap, and resuming at the full previous dose is physiologically similar to skipping the titration entirely for that dose level.